Mineralys Therapeutics (NASDAQ:MLYS) Stock Jumps 4.4% – Should You Buy?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares rose 4.4% during mid-day trading on Thursday. The company traded as high as $14.71 and last traded at $14.3810. 552,901 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,350,053 shares. The stock had previously closed at $13.78.

Analyst Ratings Changes

A number of brokerages recently weighed in on MLYS. Wall Street Zen cut Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. UBS Group began coverage on shares of Mineralys Therapeutics in a research report on Sunday, October 11th. They set a “neutral” rating and a $29.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $56.00 price target on shares of Mineralys Therapeutics in a research note on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, October 15th. Finally, Zacks Research raised shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Mineralys Therapeutics has an average rating of “Hold” and an average target price of $43.60.

Get Our Latest Research Report on MLYS

Mineralys Therapeutics Price Performance

The stock has a market cap of $1.25 billion, a PE ratio of -3.29 and a beta of 0.83. The business has a fifty day simple moving average of $21.72 and a two-hundred day simple moving average of $25.92. The company has a current ratio of 11.83, a quick ratio of 11.83 and a debt-to-equity ratio of 0.15.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). Research analysts forecast that Mineralys Therapeutics, Inc. will post -4.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Brian Slingsby sold 104,320 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total transaction of $3,005,459.20. Following the transaction, the director directly owned 7,805,718 shares of the company’s stock, valued at $224,882,735.58. This represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the completion of the sale, the director directly owned 6,200 shares of the company’s stock, valued at approximately $177,196. This trade represents a 32.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,195 shares of company stock worth $5,403,069 over the last three months. Company insiders own 18.94% of the company’s stock.

Institutional Investors Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Timothy G. Youngquist 2020 Irrevocable Trust purchased a new position in shares of Mineralys Therapeutics in the second quarter valued at $2,721,000. Man Group plc purchased a new stake in Mineralys Therapeutics during the second quarter valued at $1,609,000. Jupiter Topco LLC bought a new position in Mineralys Therapeutics during the second quarter valued at $773,000. TimesSquare Capital Management LLC bought a new position in Mineralys Therapeutics during the second quarter valued at $6,363,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Mineralys Therapeutics in the 2nd quarter worth $4,278,000. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

Recommended Stories

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.